𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Management of Sorafenib-Related Adverse Events: A Clinician’s Perspective

✍ Scribed by Brose, Marcia S.; Frenette, Catherine T.; Keefe, Stephen M.; Stein, Stacey M.

Book ID
122301750
Publisher
Elsevier Science
Year
2014
Tongue
English
Weight
242 KB
Volume
41
Category
Article
ISSN
0093-7754

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Myeloproliferative disorder therapy: ass
Myeloproliferative disorder therapy: assessment and management of adverse events—a cardiologist's perspective
✍ Dermot Kenny 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 64 KB

## Abstract Although some cardiac effects, such as palpitations and tachycardia, occur commonly in healthy people, they have also been shown to be associated with agents used to treat the myeloproliferative disorders. Various strategies exist to prevent and manage cardiac effects and minimise their

Myeloproliferative disorder therapy: ass
Myeloproliferative disorder therapy: assessment and management of adverse events—a dermatologist's perspective
✍ Boutros Soutou; Sélim Aractingi 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

## Abstract Development of cutaneous manifestations in patients with myeloproliferative disorders can be either due to the course of the disease itself or induced by some of the treatments given. The cutaneous manifestations may reveal an unknown haemopathy and/or indicate a poor prognosis. Some of

Myeloproliferative disorder therapy: ass
Myeloproliferative disorder therapy: assessment and management of adverse events—a psychiatrist's perspective
✍ Graeme McDonald 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

## Abstract Chronic diseases such as the myeloproliferative disorders may mask a worsening emotional state in patients, which can be exacerbated by the addition of common treatments such as interferon‐__α__. Management of mood disturbances is best considered from the first consultation, as the nega